Current Status and Perspectives on Pharmacologic Therapy for Abdominal Aortic Aneurysm

Koichi Yoshimura\textsuperscript{1,2,*}, Noriyasu Morikage\textsuperscript{1}, Shizuka Nishino-Fujimoto\textsuperscript{1}, Akira Furutani\textsuperscript{3}, Bungo Shirasawa\textsuperscript{4} and Kimikazu Hamano\textsuperscript{1}

\textsuperscript{1}Department of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, 755-8505, Japan; \textsuperscript{2}Graduate School of Health and Welfare, Yamaguchi Prefectural University, Yamaguchi, 753-8502, Japan; \textsuperscript{3}Department of Surgery, Yamaguchi Rosai Hospital, Sanyo-Onoda, 756-0095, Japan; \textsuperscript{4}Department of Medical Education, Yamaguchi University Graduate School of Medicine, Ube, 755-8505, Japan

Abstract: Background: Abdominal aortic aneurysm (AAA), a common disease involving the segmental expansion and rupture of the aorta, has a high mortality rate. Therapeutic options for AAA are currently limited to surgical repair to prevent catastrophic rupture. Non-surgical approaches, particularly pharmacotherapy, are lacking for the treatment of AAA.

Objective: We review both basic and clinical studies and discuss the current challenges to developing medical therapy that reduces AAA progression.

Results: Studies using animal models of AAA progression and human AAA explant cultures have identified several potential targets for preventing AAA growth. However, no clinical studies have convincingly confirmed the efficacy of any pharmacologic treatment against the growth of AAA. Thus, there is as yet no strong recommendation regarding pharmacotherapy to reduce the risk of AAA progression and rupture.

Conclusion: This review identifies concerns that need to be addressed for the field to progress and discusses the challenges that must be overcome in order to develop effective pharmacotherapy to reduce AAA progression in the future.

Keywords: Abdominal aortic aneurysm, pharmacologic therapy, medical management, progression, animal study, clinical study, practice guideline, future perspective.

1. INTRODUCTION

Abdominal aortic aneurysm (AAA) is a common disease that causes segmental dilatation and rupture of the aorta. AAA has a high mortality rate, especially in older men [1, 2]. Patients with large AAAs that are at high risk of rupture are treated by surgical repair. However, when surgical treatment is not an option, an AAA inevitably progresses, increasing in diameter and consequently increasing the rupture risk. Notably, close observation alone is recommended for patients with small AAAs; there are no alternatives to surgical repair that are available for these patients. There have been considerable efforts focused on developing medical treatments, especially pharmacotherapy, for AAA [3-7]. AAA is characterized by chronic inflammation and by the degradation of the extracellular matrix (ECM) by proteolytic enzymes, such as matrix metalloproteinases (MMPs); together, these lead to segmental dilatation of the aortic wall and eventually to rupture [7-10]. Although the real cause of AAA onset remains unknown, AAA progression is thought to be driven by factors that include hemodynamic stress and smoking. These multifactorial causes accelerate the immune and inflammatory responses in AAA tissue. Various inflammatory mediators, such as cytokines, chemokines, and prostaglandins, as well as the renin-angiotensin system, are involved in maintaining and augmenting the inflammatory responses, including inflammatory cell infiltration. Intracellular signaling molecules, such as c-Jun N-terminal kinase (JNK) and nuclear factor-κB (NF-κB), are activated by most inflammatory mediators, while activated signaling pathways enhance the expression of inflammatory mediators, thus propagating a vicious cycle of chronic inflammation. In turn, inflammatory signaling pathways activate ECM degradation enzymes, such as MMP-9, and lead to vascular smooth muscle cell (VSMC) dysfunction, thereby causing an overall loss of elastic fibers and AAA progression (Fig. 1). These mechanisms are supported by accumulating evidence that the progression of AAA in animal models can be suppressed by...
pharmacologic intervention that target various aspects of these pathophysiological processes.

![Diagram](image)

Fig. (1). The pathophysiological processes underlying the progression of AAA. Immune and inflammatory responses may be driven by the indicated causes in aortic tissues, leading to ECM degradation and VSMC dysfunction, thereby resulting in AAA progression. The pharmacologic agents discussed in this review target one or more of these processes. AAA, abdominal aortic aneurysm; ECM, extracellular matrix; MMPs, matrix metalloproteinases; VSMC, vascular smooth muscle cell.

2. CURRENT STATUS

2.1. Basic Studies of Pharmacologic Therapy for AAA

2.1.1. Studies Using Animal Models of AAA Progression

Although researchers have identified a large number of potential targets for the treatment of AAA, a limited number of them have been investigated using in vivo animal models of AAA progression. Golledge et al. noted that many rodent studies assess the effect of interventions in limiting AAA development rather than the effect of the agent on pre-established AAA [5]. Importantly, current animal models of AAA, including the elastase model, calcium chloride model, xenograft model, and angiotensin II model, have two disease phases: first, the initial development phase, which is model-specific; second, the progression phase, which mostly recapitulates human disease [11, 12]. An intervention that is used throughout the entire experimental period cannot distinguish between effects on the progression phase versus effects on the initial development phase. This review focuses on studies that have demonstrated that the pharmacologic intervention inhibits the progression phase of preexisting AAA in animal models (Table 1). In these studies, interventions were started after the initial development of AAA, and the primary outcome was a change in AAA growth that was assessed by measuring the maximal aortic diameter.

Most of the interventions shown in Table 1 target immune/inflammatory responses among several aspects during AAA progression. Specifically, these interventions demonstrated that regulating proinflammatory mediators, including cytokines [13-15], the renin-angiotensin system [16, 17], and prostaglandin metabolism [18, 19], was effective in slowing the progression of preexisting AAA. Treatment with immunosuppressive agents [20, 21] and interventions that inhibit inflammatory signaling pathways [22-24] were also shown to be effective in stopping AAA progression. Indeed, our group reported previously that treatment with the JNK-specific inhibitor SP600125 after AAA formation reduced the diameter of the aneurysm and restored the once-disrupted elastic lamellae [22]. Our recent study also demonstrated that phase-limited inhibition of focal adhesion kinase (FAK) could block further progression of pre-existing AAA in a mouse model [25]. In addition, interventions that abrogate ECM degradation using MMP inhibitors [26, 27] or pentagalloyl glucose (PGG) [28, 29] are effective in preventing AAA progression. Recently, the pharmacological inhibition of necroptosis was reported to stabilize preexisting AAA [30].

2.1.2. Studies Using Human AAA Explant Cultures

Although animal studies have been important for demonstrating proof-of-concept and for assessing the efficacy and safety of new pharmacologic therapies, there are considerable differences in the pathophysiology of humans versus animal models. Accordingly, experiments that use ex vivo cultures of human AAA tissue are conducted in addition to animal studies [22, 36, 37]. The major advantage of ex vivo cultures is that one can apply therapeutic agents directly to human tissue, bypassing concerns about systemic effects or safety. However, there is always the question of whether an agent will have a similar effect in vivo. Thus, in vivo animal models and ex vivo cultures of human tissue are complementary approaches. Although the widespread use of endovascular aneurysm repair (EVAR) is making it more difficult to utilize human AAA tissues, both types of studies are valuable and contribute to our understanding of AAA. Table 2 summarizes the studies that have investigated pharmacologic therapy in human AAA explant cultures. These studies mainly assessed the secretion or the production levels of marker proteins, such as MMPs, interleukins, and monocyte chemotactic proteins (MCPs), rather than using the AAA growth rate as in in vivo studies.

Most of the interventions shown in Table 2 targeted the immune/inflammatory responses during AAA progression, except for one study that showed the effectiveness of an MMP inhibitor [36]. Interventions that regulate proinflammatory mediators, including cytokines [38], the renin-angiotensin system [39, 40], and prostaglandin metabolism [41-44], reduced the levels of AAA-related markers. Interventions that inhibit inflammatory signaling pathways were also effective in human AAA tissues [22, 25, 45]. In addition, our group demonstrated that 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) inhibit the Rac1/NF-κB pathway, thereby suppressing MMP-9 and chemokine secretion in human AAA walls [46].

2.2. Clinical Studies of Pharmacologic Therapy for AAA

2.2.1. Previous and Ongoing Clinical Trials

Clinical trials are critical for developing new ways to treat diseases. A single randomized clinical trial or multiple
Table 1. Pharmacologic therapy that prevents AAA progression in animal models.

| Authors          | Year | Animal Model | AAA Inducer | Intervention (Period)                      | Target          | Effect on Progression of Preexisting AAA |
|------------------|------|--------------|-------------|-------------------------------------------|-----------------|-----------------------------------------|
| Huffman et al.   | 2000 | Rats         | Elastase    | Doxycycline (daily on days 7–21)          | MMP             | Stopped progression (on day 21)         |
| Yoshimura et al. | 2005 | Mice         | CaCl₂       | SP600125 (daily on days 43–84)           | JNK             | Stopped progression (on day 84)         |
|                  |      | Apoe−/− mice | Ang II      | SP600125 (daily on days 29–84)           |                 | Stopped progression (on day 84)         |
| Isenburg et al.  | 2007 | Rats         | CaCl₂       | PGG (local injection on days 28)         | Elastolytic deg- | Decreased progression (on day 56)       |
|                  |      |              |             |                                           | radation        |                                         |
| Yoshimura et al. | 2005 | Apoe−/− mice | Ang II      | Candesartan (daily on days 28–168)       | Ang II receptor | Decreased progression (on day 168)       |
|                  |      |              |             |                                           | ACE             | Decreased progression (on day 168)       |
| Dai et al.       | 2011 | Rats         | Xenograft   | Cyclosporine A (daily on days 14–21)     | Immune response | Decreased progression (on day 70)        |
| Ghoshal et al.   | 2012 | Apoe−/− mice | Ang II      | Celecoxib (daily on days 21–56)          | COX-2           | Stopped progression (on day 56)         |
|                  |      |              |             | Edaravone (daily on days 7–28)           | ROS             | Stopped progression (on day 28)         |
| Morimoto et al.  | 2012 | Rats         | Elastase and CaCl₂ |   | Decreased progression (on day 96)       |
|                  |      |              |             |                                           |                 |                                         |
| Mukherjee et al. | 2012 | Mice         | Ang II      | Celecoxib (daily on days 5–28)           | COX-2           | Decreased progression (on day 28)       |
| Johnston et al.  | 2013 | Mice         | Elastase    | Anakinra (continuously on days 7–21)     | IL-1β           | Decreased progression (on day 21)       |
| Iida et al.      | 2013 | Mice         | Elastase    | MKEY peptide (daily on days 5–14)        | CXCL4–CCL5      | Stopped progression (on day 14)         |
| Rouet et al.     | 2014 | Mice         | Elastase    | Rapamycin (daily on days 4–10)           | Immune response | Decreased progression (on day 10)        |
| Seto et al.      | 2014 | Apoe−/− mice | Ang II      | Aliskiren (daily on days 29–56)          | Renin           | Decreased progression (on day 56)       |
|                  |      |              |             |                                          |                 |                                         |
| Michineau et al. | 2014 | Mice         | CaCl₂       | AMD3100 (continuously on days 4–14)      | SDF-1/CXCR4     | Decreased progression (on day 14)       |
|                  |      |              | Xenograft   | AMD3100 (continuously on days 14–42)     |                 | Decreased progression (on day 42)       |
| Cheng et al.     | 2014 | Apoe−/− mice | Ang II      | DAPT (3 times a week on days 8–28)       | Notch           | Decreased progression (on day 28)       |
| Yan et al.       | 2015 | Mice         | CaCl₂       | TLR2-neutralizing antibody (weekly on days 42–84) | TLR2           | Decreased progression (on day 84)       |
| Nosoudi et al.   | 2015 | Rats         | CaCl₂       | Nanoparticles loaded with batimastat (weekly on days 10–38) | MMP            | Stopped progression (on day 38)         |
| Ren et al.       | 2016 | Mice         | Elastase    | Andrographolide (daily on days 7–14)     | Inflammation    | Decreased progression (on day 14)       |
| Moran et al.     | 2016 | Apoe−/− mice | Ang II      | B9330 (every other day on days 29–56)    | B2R            | Stopped progression (on day 56)         |
|                  |      |              |             | B9330 (single injection on days 7)       |                 | Decreased progression (on day 28)       |

(Table 1) contd....
| Authors              | Year | Animal Model | AAA Inducer | Intervention (Period)                          | Target       | Effect on Progression of Preexisting AAA |
|---------------------|------|--------------|-------------|-----------------------------------------------|--------------|-----------------------------------------|
| Nosoudi et al. [29] | 2016 | Rats         | CaCl₂       | PGG-loaded nanoparticles (every other week on days 10–38) | Elastolytic degradation | Decreased progression (on day 38) |
| Pope et al. [34]    | 2016 | Mice         | Elastase    | Resolvin D2 (every third day on days 3–14)     | Inflammation | Decreased progression (on day 14) |
| Harada et al. [25]  | 2017 | Mice         | CaCl₂       | PF573228 (daily on days 22–42)                | FAK          | Stopped progression (on day 42)  |
| Di Gregoli et al. [35] | 2017 | Apoe-/- or Ldlr-/- mice | Ang II (for 28 days) | mir-181b LNA inhibitor (weekly on days 29–42) | TIMP-3       | Decreased progression (on day 42) |
| Wang et al. [30]    | 2017 | Mice         | Elastase    | Necrostatin-1s (daily on days 7–14)           | Necroptosis  | Stopped progression (on day 14)  |

AAA = abdominal aortic aneurysm; ACE = angiotensin converting enzyme; Ang II = angiotensin II; Apoe-/- = apolipoprotein E deficient; B 2R = kinin B2 receptor; COX-2 = cyclooxygenase-2; FAK = focal adhesion kinase; IL-1β = interleukin-1β; JNK = c-Jun N-terminal kinase; Ldlr-/- = low density lipoprotein receptor deficient; LNA = locked nucleic acid; MMP = matrix metalloproteinase; mTOR = mammalian target of rapamycin; PGG = pentagalloyl glucose; ROS = reactive oxygen species; SDF-1 = stromal cell-derived factor 1; TIMP-3 = tissue inhibitor of metalloproteinase-3; TLR2 = toll-like receptor 2.

| Authors              | Year | Intervention | Target       | Effect on Human AAA in Ex Vivo Culture                |
|---------------------|------|--------------|--------------|-------------------------------------------------------|
| Franklin et al. [36] | 1999 | Tetracycline | MMP          | Reduced secretion of MMP-9 and MCP-1                  |
| Franklin et al. [41] | 1999 | Indomethacin | COX-2        | Reduced secretion of PGE2, IL-1β, and IL-6             |
| Walton et al. [42]  | 1999 | Indomethacin | COX-2        | Reduced secretion of PGE2, IL-1β, and IL-6             |
| Nagashima et al. [47]| 2002 | Cerivastatin | Mevalonate pathway | Reduced secretion of MMP-9                           |
| Bayston et al. [43] | 2003 | Indomethacin | COX-2        | Reduced secretion of IL-6                             |
|                    |      | Dexamethasone| COX-2        | Reduced secretion of IL-6                             |
| Nagashima et al. [48]| 2004 | Trapidil     | CD40-CD40L interaction | Reduced production of MMP-2                         |
|                    |      | Anti-CD154 antibody | CD40-CD40L interaction | Reduced production of MMP-2                         |
| Moran et al. [39]  | 2005 | Irbesartan   | Angiotensin II receptor | Reduced secretion of OPG                              |
| Dai et al. [38]    | 2005 | Recombinant human active TGF-β1 | TGF-β1 | Reduced secretion of MMP-9 and MMP-2                  |
| Yoshimura et al. [22]| 2005 | SP600125     | JNK          | Reduced secretion of MMP-9 under basal and TNF-α-stimulated conditions |
| Moran et al. [49]  | 2009 | Rosiglitazone (PPARγ agonist) | PPARγ | Reduced secretion and production of OPG, production of MMP-9, and secretion of IL-6 |
|                    |      | Pioglitazone (PPARγ agonist) | PPARγ | Reduced secretion and production of OPG, production of MMP-9, and secretion of IL-6 |
| Shintani et al. [40]| 2011 | Recombinant human HGF | | Reduced secretion of MCP-1 under TNF-α-stimulated conditions |
|                    |      | Imidaprilat  | ACE          | Reduced secretion of MCP-1 under TNF-α-stimulated conditions |
|                    |      | Perindoprilat| ACE          | Reduced secretion of MCP-1 under TNF-α-stimulated conditions |

(Table 2) contd....
large non-randomized studies are needed to provide unambiguous evidence to support the safety and efficacy of pharmacologic therapy for AAA. A large cohort study and a systematic review of clinical trials for AAA treatment were conducted previously [51, 52]. In this article, we focus on randomized clinical trials of pharmacologic interventions for AAA (Tables 3 and 4). All of these randomized clinical trials aimed to evaluate the efficacy of a pharmacologic therapy in limiting the progression of small AAA. Therefore, growth rate was commonly used as the primary outcome, and the maximal AAA diameter was measured using ultrasonography (US). Computed tomography (CT) and magnetic resonance imaging (MRI) is currently being used to assess the AAA diameter in ongoing trials. Indeed, AAA diameter remains the most widely used and the most important marker of disease progression, because large diameter and a rapid increase in the AAA diameter are thought to be risk factors for rupture and are generally accepted as an indication for surgical repair [53]. Notably, there is large individual variability in growth patterns. The sample sizes in previous trials varied, but current (ongoing) trials are larger, with more than 100 patients, and they have follow-up periods greater than one year.

*Chlamydia pneumoniae* is suspected to play a pathogenic role in AAA development, although this has not been proven. Accordingly, several randomized clinical trials have been conducted to test the efficacy of antibiotic treatment. Mosorin et al. first published a randomized trial of doxycycline, a tetracycline antibiotic, in patients with small AAAs. They showed that the expansion rate of AAAs treated with doxycycline was slower than with placebo, but the difference did not reach statistical significance [54]. Treatment with roxithromycin, a macrolide antibiotic, significantly reduced the AAA expansion rate [55, 56]. However, it is not clear whether the effect was due to its anti-microbial or anti-inflammatory activities. Later, a randomized clinical trial of azithromycin, another macrolide antibiotic, was conducted in a larger population, but found no effect on the AAA growth rate [57]. More recently, the effect of doxycycline, which was tested as an MMP inhibitor, was examined in a randomized clinical trial in a larger number of patients. That trial found that doxycycline treatment did not reduce AAA growth [58]. Propranolol, a β-blocker, was one of the first drugs to successfully inhibit the development of experimental AAAs in animal models [59, 60], and this prompted researchers to conduct clinical studies to test its effect on the growth of small AAAs. However, in a randomized trial, patients with AAAs did not tolerate propranolol well, and the drug did not significantly affect the growth rate of small AAAs [61]. Also recently, two randomized trials of pemirolast [62], a mast cell inhibitor, and perindopril [63], an angiotensin-converting enzyme (ACE) inhibitor, were conducted, but the results were disappointing (Table 3).

| Authors       | Year | Intervention                      | Target | Effect on Human AAA in Ex Vivo Culture                                                                 |
|---------------|------|-----------------------------------|--------|-----------------------------------------------------------------------------------------------------|
| Yokoyama [44] | 2012 | ONO-AE3-208 (EP4 antagonist)       | EP4    | Reduced secretion of MMP-2 and production of IL-6                                                   |
| Vucevic [50]  | 2012 | Recombinant human IL-10           | Immune response | Reduced secretion of IL-6 under PMA-stimulated conditions                                             |
| Yamashita [45]| 2013 | PF573228                          | FAK    | Reduced activation levels of ERK and JNK, and reduced secretion of MCP-1 and MMP-9                   |
| Yoshimura [46]| 2015 | Simvastatin                       | Mevalonate pathway | Reduced activation levels of JNK and NF-kB under TNF-α-stimulated conditions │ Reduced secretion of MMP-9, MCP-2, and CXCL-5 under basal and TNF-α-stimulated conditions |
| Pitavastatin  |      | Mevalonate pathway                |        | Reduced secretion of MMP-9, MCP-2, and CXCL-5 under basal and TNF-α-stimulated conditions            |
| NSC23766      |      | Rac1                              |        | Reduced secretion of MMP-9, MCP-2, and CXCL-5 under basal and TNF-α-stimulated conditions            |
| Moran [33]    | 2016 | B9330                             | B2R    | Reduced secretion of MMP-9, OPG, and osteopontin                                                    |
| Harada [25]   | 2017 | PF573228                          | FAK    | Reduced secretion of MCP-1 and MMP-9 under TNF-α-stimulated conditions                              |

AAA = abdominal aortic aneurysm; ACE = angiotensin converting enzyme; B2R = kinin B2 receptor; COX-2 = cyclooxygenase-2; EP4 = prostanoid receptor EP4; ERK = extracellular signal-regulated kinase; FAK = focal adhesion kinase; HGF = hepatocyte growth factor; IL-1β = interleukin-1β; IL-6 = interleukin-6; IL-10 = interleukin-10; JNK = c-Jun N-terminal kinase; MCP = monocyte chemotactic protein; MMP = matrix metalloproteinase; NF-kB = nuclear factor-kB; OPG = osteoprotegerin; PGE2 = prostaglandin E2; PMA = phorbol myristate acetate; PPARγ = peroxisome proliferator-activated receptor-γ; TGF-β1 = transforming growth factor-β1; TNF-α = tumor necrosis factor-α.
Table 3. Completed randomized clinical trials of pharmacologic therapy to prevent AAA progression.

| Authors          | Year | Intervention            | Sample Size | Follow-up, Months | Growth Rate, mm/year | p-value |
|------------------|------|-------------------------|-------------|-------------------|----------------------|---------|
| Mosorin et al.   | 2001 | Doxycycline (3 months)  | 32          | 18                | 1.5                  | 3.0     | NS      |
| Vammen et al.    | 2001 | Roxithromycin (28 days) | 92          | 18                | 1.56                 | 2.75    | 0.02    |
| PATI [61]        | 2002 | Propranolol             | 548         | 30                | 2.2                  | 2.6     | NS      |
|                  |      | (High dropout rate and low QOL score) |           |                   |                      |         |
| Hogh et al. [56] | 2009 | Roxithromycin (28 days) | 84          | 60                | 1.61                 | 2.52    | 0.055   |
| Karlsson et al.  | 2009 | Azithromycin (15 weeks) | 247         | 18                | 2.2                  | 2.2     | NS      |
| Meijer et al.    | 2013 | Doxycycline             | 286         | 18                | 4.1 (higher than placebo) | 3.3   | 0.016   |
| Silessen et al.  | 2015 | Pemirolast              | 326         | 12                | 2.58 (10 mg)         | 2.34 (25 mg) | 2.71 (40 mg) | 2.04 | NS      |
| Bicknell et al.  | 2016 | Perindopril             | 227         | 24                | 1.77 (perindopril) 1.81 (amlodipine) | 1.68 | NS      |

AAA = abdominal aortic aneurysm; NS = not significant; PATI = propranolol aneurysm trial investigators; QOL = quality of life.

Table 4. Ongoing randomized clinical trials of pharmacologic therapy to prevent AAA progression.

| NCT Number      | Intervention | Phase | Primary Outcome | Status                  | Estimated Completion Date | Sample Size |
|-----------------|--------------|-------|-----------------|-------------------------|---------------------------|-------------|
| NCT01756833     | Doxycycline  | 2     | Growth by CT at 48 months | Ongoing but not recruiting | September 2019            | 261         |
| NCT02070653     | Ticagrelor   | 2     | Growth by MRI at 24 months | Ongoing but not Recruiting | July 2017                 | 145         |
| NCT01683084     | Telmisartan  | 4     | Growth by CT at 48 months | Ongoing but not recruiting | August 2017               | 300         |
| NCT01904981     | Valsartan vs. Atenolol | 4 | Growth by CT at 12 months | Unknown | October 2016 | 400 |
| NCT02225756     | Cyclosporine A | 2 | Growth by CT at 12 months | Recruiting | September 2018 | 360 |
| NCT02345590     | Eplerenone   | 4     | Growth by MRI at 12 months | Recruiting | December 2019 | 172 |

AAA = abdominal aortic aneurysm; CT = computed tomography; MRI = magnetic resonance imaging; NCT = National Clinical Trial.

effect of statins has not been confirmed in larger non-randomized clinical trials [68, 69]; notably, a randomized clinical trial of statins may not be feasible, because statins are already prescribed to many patients with AAA [70].

2.2.2. Recommendation in Clinical Practice Guidelines

Several practice guidelines strongly recommend that patients with a fusiform AAA measuring 5.5 cm or larger undergo repair in the absence of significant co-morbidities and
that most patients with a fusiform AAA measuring 5.4 cm or smaller should be monitored. These guidelines include the American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines [71], the Society for Vascular Surgery (SVS) Guidelines [72], the AAA Guidelines of the European Society for Vascular Surgery (ESVS) [2], and the European Society of Cardiology (ESC) Guidelines [73]. Notably, all strongly recommend smoking cessation to slow AAA growth. However, there is no strong recommendation regarding pharmacotherapy to reduce the risk of AAA progression and rupture. At the present time, there is only a very weak recommendation that the use of statins and ACE inhibitors be considered to reduce the risk of AAA growth [72, 73]. Table 5 summarizes recommendations for the medical management of AAA in the current practice guidelines.

3. FUTURE PERSPECTIVE

3.1. Pharmacologic Therapy for Primary Prevention

Because AAA is life-threatening, preventing AAA rupture is an important goal. We are hopeful that in the future, pharmacologic treatment will play a key role in the primary, secondary, and tertiary prevention of AAA (Table 6). In primary prevention, the goal of pharmacotherapy is to reduce the incidence of AAA, but there is not yet a clear way to do this due to a lack of understanding of the mechanisms underlying AAA. Although it is widely accepted that multifactorial causes, including smoking and hypertension, drive the progression of AAA (Fig. 1), the primary cause of AAA onset remains unclear. If the cause is identified, a drug or drugs can be identified or developed and utilized to prevent the onset of AAA. Therefore, researchers should continue to investigate the pathogenesis underlying AAA.

| Guidelines | Year | Recommendation | Class of Recommendation | Level of Evidence |
|------------|------|----------------|------------------------|-----------------|
| ESC [73]   | 2014 | Encourage smoking cessation to slow the growth of the AAA. | I (Evidence and/or general agreement that a given treatment or procedure in beneficial, useful, effective.) | B (Data derived from a single randomized clinical trial or large non-randomized studies.) |
| SVS [72]   | 2009 | Consider the use of statins and ACE inhibitors to reduce aortic complications in patients with small AAAs. | IIb (Usefulness/efficacy is less well established by evidence/opinion.) | B (Data derived from a single randomized clinical trial or large non-randomized studies.) |
|            |      | Encourage smoking cessation to reduce the risk of AAA growth and rupture. | Strong | High |
|            |      | Consider the use of statins to reduce the risk of AAA growth. | Weak | Low |
|            |      | Uncertain benefits for the use of doxycycline, roxithromycin, ACE inhibitors, and ARBs for reducing the risk of AAA expansion and rupture. | Weak | Low |
|            |      | Do not use β-blockers to reduce the risk of AAA expansion and rupture. | Strong | Moderate |

There are several known risk factors that contribute to AAA development, such as hypertension and hypercholesterolemia [72]. The incidence of AAA might be reduced by appropriate pharmacologic treatment of these risk factors. Avoiding the risk factors and increasing physical activity to reduce the risk factors might also reduce the incidence of AAA. Moreover, the pharmacologic management of cardiovascular risk factors is generally important in people at high risk of developing AAA [2].

3.2. Pharmacologic Therapy for Secondary Prevention

The goal of pharmacotherapy for the secondary prevention of AAA is to reduce disease progression and the risk of surgical referral. Many patients presenting with AAAs measuring less than 5.5 cm are simply monitored, while treatments such as surveillance or early repair remain controversial in the management of patients with AAAs between 4.0 cm and 5.4 cm in diameter [72, 73]. Therefore, pharmacologic therapy to prevent AAA progression, or ideally to reverse AAA formation, would have a huge impact on the management of patients with small AAA once it is established and becomes a first-line treatment, replacing surveillance and early repair.

Unfortunately, no pharmacotherapy for AAA has been realized despite great effort, and there are several challenges that need to be addressed (Table 7). First, it is possible that appropriate drug targets in human AAA have not been identified. Indeed, many animal studies have assessed the effects of interventions in limiting AAA development rather than the effects on pre-established AAA. In addition, the experimental opportunities for analyzing human AAA specimens...
have decreased in recent years. To gain a better understanding of human AAA pathophysiology and pathogenesis, continued efforts are essential, including the appropriate use and interpretation of animal models and full utilization of human samples. Second, it is important for pharmacotherapy to be sufficiently concentrated at the AAA site, but few pharmacokinetic approaches have been tested. Golledge et al. suggested that inappropriate dosage may underlie the negative findings in previous clinical trials [5]. Since AAA is predominately localized to a limited site on the aorta, it is reasonable to strive for local delivery of therapeutic agents in order to increase therapeutic efficacy and reduce systemic side effects. The efficacy of local administration was previously reported using doxycycline in rodent models of AAA [74, 75]. Notably, Nosoudi et al. recently reported the effects of AAA-targeted delivery of drugs using nanoparticles [27, 29], which seems to represent an attractive strategy for inhibiting AAA progression. Third, there is a possibility that the heterogeneity of human AAA might not be fully appreciated or taken into account when testing therapeutic agents, since patients with AAA are heterogeneous in terms of their characteristics, clinical history, and genetic background [10, 76]. In addition, human AAA tissue itself is spatiotemporally heterogeneous in terms of histopathological characteristics [7]. Therefore, it may be better to stratify AAA patients according to the predominant biological activities; towards this end, we must identify biomarkers that accurately reflect biological activity in AAA. If we can optimize therapeutic regimens for individual patients using biomarkers (personalized medicine), we may be able to achieve more effective outcomes with pharmacologic therapy and prevent or slow AAA progression.

### 3.3. Pharmacologic Therapy for Tertiary Prevention

In tertiary prevention, the goal of pharmacotherapy is to reduce AAA-related complications and mortality in patients with AAAs measuring 5.5 cm or larger. In the absence of significant co-morbidities, these patients should undergo surgical repair. Accordingly, pharmacotherapy for tertiary prevention is expected to serve as an adjuvant treatment to reduce peri- and postoperative complications as well as to improve the results of EVAR. The ESVS guidelines [2] already recommend that statins be started one month prior to surgical intervention to reduce cardiovascular morbidity, since statin therapy improves perioperative and postoperative outcomes after AAA repair [77-79]. β-blockers are also recommended for patients with ischemic heart disease, and these can be started one month before the intervention [2, 71]. Because AAA patients often have several comorbidities that significantly affect the outcome of AAA repair, preoperative care strategies, especially pharmacotherapy, may help improve post-intervention morbidity and mortality.

Notably, ongoing aortic wall degeneration and the subsequent failure of aneurysm exclusion, such as endoleaks, is a major concern after EVAR. To address this concern, adjuvant pharmacotherapy concomitant to or after EVAR could provide an ideal solution. Several studies have suggested a potential association between aneurysm sac regression and treatment with drugs like statins [80, 81], doxycycline [82], calcium channel blockers [83], and tranexamic acid [84]. However, the use of pharmacotherapy remains controversial because of inconsistent results [85]. Further studies are needed to clarify the role of adjuvant pharmacotherapy in enhancing sac regression and in reducing the risk of

### Table 6. Possible future roles of pharmacologic treatments in the management of AAA.

| Level of Prevention | Target Population | Treatment Goal | Possible Treatment Strategies |
|---------------------|-------------------|----------------|------------------------------|
| Primary prevention  | At-risk patients  | Reduce the incidence of AAA. | Use pharmacologic treatment of risk factors for AAA, such as hypertension and hypercholesterolemia. |
| Secondary prevention| Patients with small AAAs | Reduce the progression of AAA and the risk of surgical referral. | Use pharmacologic therapy to stop or slow the progression of AAA. |
| Tertiary prevention | Patients with large AAAs | Reduce AAA-related complications and mortality. | Use adjuvant pharmacologic treatment to reduce peri- and postoperative complications and to improve EVAR results. |

AAA = abdominal aortic aneurysm; EVAR = endovascular aneurysm repair.
CONCLUSION

Research conducted over the last 25 years has substantially deepened our understanding of the pathophysiology underlying AAA. However, this understanding has not translated into the development of pharmacologic therapies that improve the outcomes of AAA patients. Going forward, strategic approaches must be developed to continue to make progress in AAA research in order to offer effective pharmacotherapy to patients in addition to open repair and EVAR.

LIST OF ABBREVIATIONS

AAA = Abdominal aortic aneurysm
ACC = American College of Cardiology
ACE = Angiotensin-converting enzyme
AHA = American Heart Association
Ang II = Angiotensin II
Apoe-/- = Apolipoprotein E deficient
ARB = Angiotensin receptor blocker
B2R = Kinin B2 receptor
COX-2 = Cyclooxygenase-2
CT = Computed tomography
DDS = Drug delivery system
ECM = Extracellular matrix
EP4 = Prostanoid receptor EP4
ERK = Extracellular signal-regulated kinase
ESC = European Society of Cardiology
ESVE = European Society for Vascular Surgery
EVAR = Endovascular aneurysm repair
FK = Focal adhesion kinase
HGF = Hepatocyte growth factor
HMG-CoA = 3-hydroxy-3-methylglutaryl-coenzyme A
IL-1β = Interleukin-1β
IL-6 = Interleukin-6
IL-10 = Interleukin-10
JNK = c-Jun N-terminal kinase
Ldr/-/- = Low density lipoprotein receptor deficient
LNA = Locked nucleic acid
MCP = Monocyte chemotactic protein
MMP = Matrix metalloproteinase
MRI = Magnetic resonance imaging
mTOR = Mammalian target of rapamycin
NF-κB = Nuclear factor-κB
NS = Not significant
OPG = Osteoprotegerin
PATI = Propranolol aneurysm trial investigators
PGE2 = Prostaglandin E2
PGG = Pentaglycolloy glucose
PMA = Phorbol myristate acetate
PPARγ = Peroxisome proliferator-activated receptor-γ
QOL = Quality of life
RCT = Randomized controlled trial
ROS = Reactive oxygen species
SDF-1 = Stromal cell-derived factor 1
SVS = Society for Vascular Surgery
TGF-β1 = Transforming growth factor-β1
TIMP-3 = Tissue inhibitor of metalloproteinase-3
TLR2 = Toll-like receptor2
TNF-α = Tumor necrosis factor-α
US = Ultrasonography
VSMC = Vascular smooth muscle cell

CONSENT FOR PUBLICATION

Not applicable.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

This work was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (KAKENHI to Koichi Yoshimura).

REFERENCES

[1] Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet 2005; 365: 1577-89.
[2] Moll FL, Powell JT, Friedrich G, et al. Management of abdominal aortic aneurysms clinical practice guidelines of the European Society for Vascular Surgery. Eur J Vasc Endovasc Surg 2011; 41 (Suppl 1): S1-S58.
[3] Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. Circulation 2008; 117: 1883-9.
[4] Golledge J, Powell JT. Medical management of abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2007; 34: 267-73.
[5] Golledge J, Norman PE, Murphy MP, Dalman RL. Challenges and opportunities in limiting abdominal aortic aneurysm growth. J Vasc Surg 2017; 65: 225-33.
[6] Yoshimura K, Aoki H, Ikeda Y, Furutani A, Hamano K, Matsuzaki M. Development of pharmacological therapy for abdominal aortic aneurysms based on animal studies. In: Sakalihasan N, Ed. Aortic Aneurysms, new insights into an old problem. Édition de l’Université de Liège: Liège, 2008.
[7] Yoshimura K, Aoki H. Recent advances in pharmacotherapy development for abdominal aortic aneurysm. Int J Vasc Med 2012; 2012: 648167.
[8] Thompson RW, Geraghty PJ, Lee JK. Abdominal aortic aneurysms: basic mechanisms and clinical implications. Curr Probl Surg 2002; 39: 110-230.
[9] Tedesco MM, Dalman RL. Arterial aneurysms. In: Cronenwett JL, Johnston KW, Eds. Vascular surgery. Saunders: Philadelphia, 2002; 39: 110-230.
[10] Curci JA, Baxter BT, Thompson RW. Arterial Aneurysms: Endovascular repair techniques and medical options. Saunders, Philadelphia, 2005.
[11] Senemaud J, Caligiuri G, Etienne H, Delbosc S, Michel JB, Coscas G, I'Université de Liège: Liège, 2008.
[12] Lysgaard Poulsen J, Stubbe J, Lindholdt JS. Animal models used to explore abdominal aortic aneurysms: A systematic review. Eur J Vasc Endovasc Surg 2016; 52: 487-99.
[13] Johnston WF, Salmon M, Su G, et al. Genetic and pharmacologic disruption of interleukin-1 beta signaling inhibits experimental aortic aneurysm formation. Arterioscler Thromb Vasc Biol 2013; 33: 294-304.
[14] Iida Y, Xu B, Yuan H, et al. Peptide inhibitor of CXCL4-CCL5 heterodimer formation, MKKEY, inhibits experimental aortic aneu-
Di Gregori K, Mohamad Anuar NN, Bianco R, et al. MicroRNA-181b controls atherosclerosis and aneurysms through regulation of TIMP-3 and elastin. Circ Res 2017; 120: 49-65.

Franklin IJ, Harley SL, Greenhalgh RM, Powell JT. Uptake of tetracycline by aortic aneurysm wall and its effect on inflammation and proteolysis. Br J Surg 1999; 86: 771-5.

Nagasawa A, Yoshimura K, Suzuki R, et al. Important role of the angiotensin II pathway in producing matrix metalloproteinase-9 in human thoracic aortic aneurysms. J Surg Res 2013; 183: 472-7.

Dai J, Losy F, Guinauld AM, et al. Overexpression of transforming growth factor-beta stabilizes already-formed aortic aneurysms: A first approach to induction of functional healing by endovascular gene therapy. Circulation 2005; 112: 1008-15.

Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005; 111: 3119-25.

Shintani Y, Aoki H, Nishihara M, et al. Hepatocyte growth factor promotes an anti-inflammatory cytokine profile in human abdominal aortic aneurysm tissue. Atherosclerosis 2011; 216: 307-12.

Franklin IJ, Walton LJ, Greenhalgh RM, Powell JT. The influence of indomethacin on the metabolism and cytokine secretion of human aneurysmal aorta. Eur J Vasc Endovasc Surg 1999; 18: 35-42.

Walton LJ, Franklin IJ, Bayston T, et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999; 100: 48-54.

Bayston T, Ramesurr S, Reise J, Jones KG, Powell JT. Prostaglandin E2 receptors in abdominal aortic aneurysm and human aortic smooth muscle cells. J Vasc Endovasc Surg 2003; 38: 354-9.

Yokoyama U, Ishiwata R, Jin MH, et al. Inhibition of EP4 signaling attenuates aortic aneurysm formation. PLoS One 2012; 7: e47275.

Yamashita O, Yoshimura K, et al. Periostin links mechanical strain to inflammation in abdominal aortic aneurysm. PLoS One 2013; 8: e79753.

Yoshimura K, Nagasawa A, Kudo J, et al. Inhibitory effect of statins on inflammation-related pathways in human abdominal aortic aneurysm tissue. Int J Mol Sci 2015; 16: 11213-28.

Yoshimura K, Aoka Y, Sakomura Y, et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 2002; 36: 158-63.

Nagasawa A, Yoshimura K, Suzuki R, et al. Matrix metalloproteinase-2 is suppressed by trapidil, a CD40-CD40 ligand pathway inhibitor, in human abdominal aortic aneurysm wall. J Vasc Surg 2004; 39: 447-53.

Morgan CS, Cullen B, Campbell JH, Golledge J. Interaction between angiotensin II, osteoprotegerin, and peroxisome proliferator-activated receptor-gamma agonist in a human aortic aneurysm. J Vasc Res 2009; 46: 209-17.

Vuvcic D, Maravic-Stojkovic V, Vasilijic S, et al. Inverse production of IL-6 and IL-10 by abdominal aortic aneurysm explant tissues in culture. Cardiovasc Pathol 2012; 21: 482-9.

Kristensen KE, Torp-Pedersen C, Gislason GH, Eegfjord M, Rasmussen HB, Hansen PR. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with abdominal aortic aneurysms: nation-wide cohort study. Arterioscler Thromb Vasc Biol 2015; 35: 733-40.

Kokje VBC, Hamming JF, Lindeman JHN. Editor's choice – Pharmaceutical management of small abdominal aortic aneurysms: A systematic review of the clinical evidence. Eur J Vasc Endovasc Surg 2015; 50: 702-13.

Wanhainen A, Mani K, Golledge J. Surrogate markers of abdominal aortic aneurysm progression. Arterioscler Thromb Vasc Biol 2016; 36: 236-44.

Mosorin M, Juvonen J, Bianco R, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001; 34: 606-10.

Vammen S, Lindholt JS. Intermittent roxithromycin for preventing progression of abdominal aortic aneurysm. Br J Surg 2001; 88: 1066-72.

Hogh A, Vammen S, Ostergaard L, Johansen JB, Henneberg EW, Lindholt JS. Intermittent thromboxycin for preventing progression...
of small abdominal aortic aneurysms: long-term results of a small clinical trial. Vasc Endovascular Surg 2009; 43: 452-6.

[57] Karlsson L, Gnarpe J, Bergqvist D, Lindback J, Parsson H. The effect of azithromycin and Chlamydia pneumoniae infection on expansion of small abdominal aortic aneurysms—a prospective randomized double-blind trial. J Vasc Surg 2009; 50: 23-9.

[58] Meijer CA, Stijnen T, Wasser MN, Hamming JF, van Bockel JH, Lindeman JH. Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Ann Intern Med 2013; 159: 815-23.

[59] Brophy C, Tilson JE, Tilson MD. Propranolol delays the formation of aneurysms in the male blotchy mouse. J Surg Res 1988; 44: 687-9.

[60] Ricci MA, Slaihy JM, Gadowski GR, Hendley ED, Nichols P, Pilcher DB. Effects of hypertension and propranolol upon aneurysm expansion in the Anidjar/Dobrin aneurysm model. Ann N Y Acad Sci 1996; 800: 89-96.

[61] The-Propranolol-Aneurysm-Trial-Investigators. Propranolol for small abdominal aneurysms: results of a randomized trial. J Vasc Surg 2002; 35: 72-9.

[62] Sillese H, Eldrup N, Hultgren R, et al. Randomized clinical trial of mast cell inhibition in patients with a medium-sized abdominal aortic aneurysm. Br J Surg 2015; 102: 894-901.

[63] Bicknell CD, Kuru G, Falaschetti E, Powell JT, Pouther NR. An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK). Eur Heart J 2016; 37: 3213-21.

[64] Karrwoni W, Dughman S, Haji GP, Miller FJ, Jr. Statin therapy reduces growth of abdominal aortic aneurysms. J Invest Med 2011; 59: 1239-43.

[65] Schlosser FJ, Tangelder MJ, Verhagen HJ, et al. Growth predictors and prognosis of small abdominal aortic aneurysms. J Vasc Surg 2008; 47: 1127-33.

[66] Schouten O, van Laanen JH, Boersma E, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006; 32: 21-6.

[67] Sukhija R, Aronow WS, Sandhu R, Kakar P, Babu S. Mortality and aortic aneurysm expansion in the Anidjar/Dobrin aneurysm model. Ann N Y Acad Sci 1996; 800: 89-96.

[68] Thompson AR, Drenos F, Hafez H, Humphries SE. Candidate gene association studies in abdominal aortic aneurysm disease: A review and meta-analysis. Eur J Vasc Endovasc Surg 2008; 35: 19-30.

[69] Bartoli MA, Parodi FE, Chu J, et al. Localized administration of doxycycline suppresses aortic dilatation in an experimental mouse model of abdominal aortic aneurysm. Ann Vasc Surg 2006; 20: 228-36.

[70] Su X, Baker D, Kostis JB, et al. Calcium channel blockers enhance sac shrinkage after endovascular aneurysm repair. J Vasc Surg 2017; 65: 1830-8.

[71] Thompson A, Cooper JA, Fabricius M, Humphries SE, Ashton HA, Hafez H. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg 2010; 52: 55-61 e2.

[72] Chakof EL, Brewster DC, Dalman RL, et al. The care of patients with an abdominal aortic aneurysm: The Society for Vascular Surgery practice guidelines. J Vasc Surg 2009; 50: S2-S49.

[73] Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J 2014; 35: 2873-926.

[74] Sho E, Chu J, Sho M, et al. Continuous periarterial infusion improves doxycycline efficacy in experimental aortic aneurysms. J Vasc Surg 2004; 39: 1312-21.

[75] Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J 2014; 35: 2873-926.

[76] Thompson AR, Drenos F, Hafez H, Humphries SE. Candidate gene association studies in abdominal aortic aneurysm disease: A review and meta-analysis. Eur J Vasc Endovasc Surg 2008; 35: 19-30.

[77] Twine CP, Williams IM. Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms. Br J Surg 2011; 98: 346-53.

[78] McNelly MM, Agle SC, Parker FM, Bogey WM, Powell CS, Stoner MC. Preoperative statin therapy is associated with improved outcomes and resource utilization in patients undergoing aortic aneurysm repair. J Vasc Surg 2010; 51: 1390-6.

[79] de Bruin JL, Baas AF, Heymans MW, et al. Statin therapy is associated with improved survival after endovascular and open aneurysm repair. J Vasc Surg 2014; 59: 39-44 e1.

[80] Raux M, Cochenneec F, Becquemin JP. Statin therapy is associated with aneurysm sac regression after endovascular aortic repair. J Vasc Surg 2012; 55: 1587-92.

[81] Lalys F, Daoudal A, Gindre J, Goksu C, Lucas A, Kaladji A. Influencing factors of sac shrinkage after endovascular aneurysm repair. J Vasc Surg 2017; 65: 1830-8.

[82] Hackmann AE, Rubin BG, Sanchez LA, Geraghty PA, Thompson RW, Curci JA. A randomized, placebo-controlled trial of doxycycline after endoluminal aneurysm repair. J Vasc Surg 2008; 48: 519-26.

[83] Bailey MA, Sohrabi S, Flood K, et al. Calcium channel blockers enhance sac shrinkage after endovascular aneurysm repair. J Vasc Surg 2012; 55: 1593-9.

[84] Aoki A, Suezawa T, Yamamoto S, et al. Effect of antifibrinolytic therapy with tranexamic acid on abdominal aortic aneurysm shrinkage after endovascular repair. J Vasc Surg 2014; 59: 1203-8.

[85] Kim W, Gandhi RT, Pena CS, et al. Influence of statin therapy on aneurysm sac regression after endovascular aortic repair. J Vasc Interv Radiol 2017; 28: 35-43.

[86] Aoki H, Yoshimura K, Tsutsui H, Teruya C, Matsuoka M, Kuroda S. Drug delivery system, WO/2009/082014. 2009.

[87] Deen M, Gifford H, S., Andreas B, Chew S, French R, Sutton D. Methods and devices for treating aneurysms, WO/2004/004603. 2004.